Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration

Journal of Clinical Pharmacology

Volumn 37, Issue 9, 1997, Pages 834-840

  Hu, Oliver Yoa Pu ^a,c   Ding, Philip Y A ^a   Huang, Christine Shu Hui ^a   Hwang, Giann Ming ^b   Chu, Kai Min ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FOSINOPRILAT;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PLASMA CLEARANCE; RACE DIFFERENCE;

EID: 0030822041     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb05632.x     Document Type: Article

References (32)

1. Morrison RA, Singhvi SM, Povetti D, Peterson AE, Migdalof BH: Sites of first-pass bioactivation of fosinopril sodium in dogs (abstract). Pharmacologist 1987;29:149.
2. Duchin KL, Manning JA, McKinstry DN, Willard DA: Tolerance and pharmacologic effects of SQ28,555, a new angiotensin converting enzyme (ACE) inhibitor (abstract). J Clin Pharmacol 1984;24:422.
3. DeForrest JM, Waldron TL, Harvey C, Scalese B, Rubin B, Powell JR, et al: Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology. J Cardiovasc Pharmacol 1989;14:730-736.
4. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M: Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988;25:9-15.
5. Duchin KL, Waclawski AP, Tu JT, Manning J, Frantz M, Willard DA: Pharmacokinetics, safety and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. J Clin Pharmacol 1991;31:58-64.
6. Gonzalez FJ, Idle JR: Pharmacogenetic phenotyping and genotyping. Clin Pharmacokinet 1994;26:59-70.
7. Wood AJJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-373.
8. Yue QY, Svensson JO, Sjöqvist F, Sawe J: A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:643-647.
9. Zhou HH, Sheller JR, Nu H, Wood M, Wood AJJ: Ethnic differences in response to morphine. Clin Pharmacol Ther 1993; 54:507-513.
10. Houghton IT, Chan K, Wong YC, Aun CST, Lau OW, Lowe DM: Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Find Exp Clin Pharmacol 1992;14:451-458.
11. Zhang Y, Reviriego J, Lou Y, Sjöqvist F, Bertilsson L: Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990;48:496-502.
12. Hu OYP, Chen KB, Pao LH, Kwok KM, Ho ST, Chan SF, et al: Pharmacokinetics, pharmacodynamics and relative bioavailability of propranolol tablet in Chinese. Chin Pharm J 1991; 43:413-423.
13. Hu OYP, Liou WS, Su TJ, Chiam SF, Lai JS, Chu ML, Chung PH: Pharmacokinetic properties of intramuscular gentamicin in Chinese subjects. Int J Pharm 1989;53:85-89.
14. Wang-Iverson D, Ivashiv E, Jemal M, Cohen A: Simultaneous determination of SQ 28,555 and SQ 27,519 in serum by ionspray mass spectrometry (abstract). Annual American Society for Mass Spectrometry Meeting. Nashville, Tennessee, May, 1991.
15. McLaughlin L: Quantitative determination of fosinoprilat in human urine by direct-injection LC/MS/MS. Squibb Scientific Report, 3/1/94.
16. Metzler M, Elfring G, McEwen A: A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 130:562-563.
17. Tu JI, Brennan J, Stouffer B, Eckelman WC: A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. Ther Drug Monit 1990;12:404-410.
18. Jemal M: LC/MS and RIA methods for fosinoprilat in human serum. Squibb Scientific Report, 4/4/95.
19. Hsiu KT, Yeh SJ, Leu ML: Kidney size in normal Chinese adults: assessment by renosonogram and plain roentgenogram. Chang Gung Med J 1983;6:93-99.
20. Katoh T, Higashi K: Ethic differences of the primary gene defect at the cytochrome P-450 2D6. Sangyo Ika Daigaku Zasshi 1992;14:205-209.
21. Lee EJD, Kalow W: Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993;4:28-33.
22. Ishizaki T, Sohn D, Kobayashi K, Chiba K, Lee KH, Shin S, et al: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16:214-215.
23. Kalow W: Ethnic differences in drug metabolism. Clin Pharmacokinet 1982;7:373-400.
24. Yue QY, Svensson JO, Sjöqvist F, Säwe J: A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmac 1991;31:643-647.
25. Lee SK, Tang HS, Chang TM: Gray-scale static ultrasonic scanning of liver in normal Chinese adults. J Med Sci 1989;9:393-401.
26. Lee SK, Tang HS, Chang TM: Gray-scale static ultrasonic scanning of liver diameters and volume in normal Chinese adults. J Formosan Med Assoc 1989;88:308-311.
27. Chou YH, Tiu CM, Pan HB, Chang T, Su YG: The measurement of spleno-portal venous and hepatic arterial blood flow in normal adults using duplex ultrasound - a preliminary report. Chin Med J 1985;35:343-349.
28. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N: Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991;49:457-467.
29. Duchin KL, Kripalani KJ, Marino MR, Dean AV, Natarajan CS: Review of the pharmacokinetics of fosinopril in special populations. Drug Invest 1991;3(suppl 4):18-24.
30. Zhou HH, Adedoyin A, Wilkinson GR: Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990;48:10-17.
31. Liao WC, Delancy C, Davis K, Norton J, Jemal M: A report on the pharmacokinetics and pharmacodynamics of fosinopril in congestive heart failure patients and matching controls. Bristol-Myers Squibb Report, 2/28/94.
32. Levinson B, Sugerman AA, Couchman T, Nichola P, Tu J: Advanced age per se has no influence on the kinetics of the active diacid of fosenopril (F) (abstract). J Clin Pharmacol 1986;26:555.